Wolverine blend
Multi peptide
ABOUT
Wolverine is a community nickname for BPC-157 and TB-500 co-vialled in one injection rather than two. It is not a brand and has no standard ratio: suppliers sell it between 1:1 and 1:2.
WHAT IS IN IT · 2 COMPOUNDS
Check the amounts on the vial rather than assuming them from the blend name.
EVIDENCE OVERVIEW
Too little published work to judge either way
WHAT THIS MEANS
Insufficient evidence. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
Two mechanisms that are genuinely distinct rather than duplicative, which is the honest part of the rationale: BPC-157 is credited in rodent work with angiogenesis and activation of the FAK-paxillin pathway in tendon fibroblasts, while TB-500 corresponds to the actin-binding region of thymosin beta-4 and is associated with cell migration. Neither has an identified receptor.
PHARMACOKINETICS
Neither component has a published human pharmacokinetic study, so no exposure profile exists for the pair. The ratio is set by the supplier and varies, so dose per injection is not comparable between products.
REVIEW
PUBLISHED PAIR RECORDS
with BPC-157
Same substance taken twice: blend already contains this compoundWolverine blend already contains BPC-157. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with TB-500
Same substance taken twice: blend already contains this compoundWolverine blend already contains TB-500. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with KLOW
Overlapping blends: the same compounds appear in bothKLOW and Wolverine blend both contain BPC-157, TB-500. Taking both means those shared components arrive from two vials at once, at a combined amount neither product states, while the components unique to each still arrive at their own. Because both are sold at fixed manufacturer ratios, neither can be adjusted to compensate for the other. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with GLOW
Overlapping blends: the same compounds appear in bothGLOW and Wolverine blend both contain BPC-157, TB-500. Taking both means those shared components arrive from two vials at once, at a combined amount neither product states, while the components unique to each still arrive at their own. Because both are sold at fixed manufacturer ratios, neither can be adjusted to compensate for the other. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Thymosin Beta-4
Inherited from a component of this blendWolverine blend contains BPC-157 and TB-500, and the catalogue holds a curated pair record between those components and Thymosin Beta-4: BPC-157 (commonly combined tissue-repair peptides with no combination evidence); TB-500 (same molecule family: fragment and parent protein). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
No study has examined this blend as a blend. A PubMed search for the product name returns no matching literature, so everything known about it is inference from its separate components, and the effect of giving them together at a fixed ratio is uncharacterised rather than known to be additive. This pairing is unusual in having any human report at all: a retrospective chart review of knee-pain patients given both peptides together. It had no control group and no randomisation, and cannot separate either peptide's contribution - it documents that the combination has been used, not that it works.
REPORTED EFFECTS
No systematic safety data exists for either component or the pair. Both are on FDA's Category 2 interim compounding list, and thymosin beta-4 and its derivatives - TB-500 named explicitly - are prohibited at all times in sport, with validated anti-doping assays for the synthetic fragment.
RESEARCH LIMITATIONS
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
CURATED SOURCES · 4